Categories
- All
- ETF Education
- New Rate Regime
- Quality for Volatility
- India
- Japan
- Artificial Intelligence
- Fixed Income
- Megatrends
- Emerging Markets
- Quality Dividend Growth
- Digital Assets
- Model Portfolios
- BTM Podcast Series
- Advisor Solutions Series
- Women in Asset Management Series
- Index Rebalance Series
- Currency Hedged Equity
At WisdomTree, we work with Dr. Jamie Metzl on a strategy that we term the BioRevolution. Dr. Metzl recently a book, Superconvergence: How the Genetics, Biotech, and AI Revolutions Will Transform our Lives, Work, and World. In the third part of our BioRevolution blog series, Christopher Gannatti summarizes a few key points from the book including the evolution of AlphaFold 3.
Read the article
We just passed the 20th of July, 2024, and approximately 90 days have passed since the pivotal bitcoin halving event in April. While Bitcoin flirted with all-time-high price levels earlier this year, nearing $74,000, Chris Gannatti and Blake Heimann explain why recent trends might refocus investors on the longer term.
Read the article
Nvidia isn’t the only player in the semiconductor field. Christopher Gannatti and Mobeen Tahir highlight other companies making significant strides in the semiconductor industry.
Read the article
The AI revolution is reshaping our world, and our strategies are evolving to keep pace. Christopher Gannatti analyzes our WisdomTree Artificial Intelligence & Innovation and U.S. Quality Growth Funds and provides insights into market dynamics and the influence of major AI players like Nvidia and the Magnificent 7.
Read the article
Late 2023 was a period of high hopes for interest rate cuts from the U.S. Federal Reserve. Christopher Gannatti discusses the resulting boom in SaaS stocks and their subsequent decline in the first half of 2024.
Read the article
At WisdomTree, we work with Dr. Jamie Metzl on a strategy that we term the BioRevolution. Dr. Metzl recently wrote a book, Superconvergence: How the Genetics, Biotech, and AI Revolutions Will Transform our Lives, Work, and World. In this second part of our BioRevolution blog series, Christopher Gannatti summarizes a few key points from the book including the journey to the mRNA vaccine.
Read the article
